Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday

  • Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. REGN from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to Overweight. Regeneron Pharmaceuticals shares rose 0.9% to $714.99 in pre-market trading.
  • RBC Capital boosted Zscaler, Inc. ZS price target from $200 to $210. RBC Capital analyst Matthew Hedberg maintained the stock with an Outperform rating. Zscaler shares rose 13.5% to $175.11 in pre-market trading.
  • B of A Securities cut American Axle & Manufacturing Holdings, Inc. AXL price target from $16 to $13. B of A Securities analyst John Murphy also downgraded the stock from Buy to Neutral. American Axle shares fell 2.1% to $9.66 in pre-market trading.
  • Oppenheimer cut The Lovesac Company LOVE price target from $95 to $60. Stifel analyst Parker Lane maintained a Buy rating on the stock. Lovesac shares rose 1.8% to $26.65 in pre-market trading.
  • Barclays lowered Navient Corporation NAVI price target from $19 to $13. Barclays analyst Mark Devries also downgraded the stock from Overweight to Equal-Weight. Navient fell 0.1% to $15.00 in pre-market trading.
  • Piper Sandler cut Align Technology, Inc. ALGN price target from $370 to $340. Piper Sandler analyst Jason Bednar maintained an Overweight rating on the stock. Align Technology shares rose 0.7% to $259.00 in pre-market trading.

Check out this: Why Fear Level Among US Investors Is Decreasing

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: NewsPrice TargetSmall CapPre-Market OutlookMarketsAnalyst RatingsTrading IdeasPrice Target Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!